New head of science at Australian Synchrotron talks life science research
10 February, 2011 by Tim DeanDr Andrew Peele, the new head of science for the Australian Synchrotron, talks about the road ahead for life sciences at the facility.
Immune system boosting hormone might lead to HIV cure
04 February, 2011 by Tim DeanResearchers have found that boosting the immune system cure chronic a viral infection in mice similar to HIV, opening up possible future therapies.
Applications open for 2011 Victorian Premier's Award for Health and Medical Research
03 February, 2011 by Staff WritersApplications for the 2011 Premier’s Award for Health and Medical Research are now open.
Relevare poised for IPO
02 February, 2011 by Tim DeanThanks to improving market conditions and more positive sentiment towards Australian biotechnology companies, Relevare is ready for its IPO, expected to raise $20 million, in March after putting its public listing on hiatus in mid-2010.
Opinion: Five strategies for successful commercialisation in biotechnology
01 February, 2011 by Staff WritersToday, the key factors needed to ensure small to medium biotechnology firms survive the discontinuous change are: entrepreneurship, innovation and collaboration. The following five strategies for successful commercialisation are founded on these the three key factors of success.
Market report: ResMed announces record quarterly results
28 January, 2011 by Tim DeanMedical device company, ResMed (ASX:RMD), announced a record revenue and income for the quarter ended December 31, 2010, although share price takes a hit.
Bioniche set for ASX listing on Thursday
25 January, 2011 by Tim DeanCanada-based biotechnology company, Bioniche, is all set for its listing on the Australian Securities Exchange (ASX) this Thursday.
Rapidly deteriorating growth for pharma: Datamonitor
21 January, 2011 by Staff WritersGrowth will slow to just 1.3% to 2015 for the branded prescription pharmaceutical industry’s leading companies, according to latest research from independent market analyst, Datamonitor.
Mesoblast sees positive interim results from heart stem cell trial
11 January, 2011 by Tim DeanMesoblast and its US partner Cephalon have announced promising interim results showing its stem cell therapy, Revascor, aids in the recovery of patients with congestive heart failure.
Market report: Biotechs snap six-week winning streak as wider market gains
24 December, 2010 by David BinningAustralian biotech stocks slipped into the red for the first week in seven today while the wider market managed to sneak into the black.
Novogen finalises IP sale deal with US subsidiary
22 December, 2010 by David BinningCancer specialists Novogen announced today that it has finalised the sale of its portfolio of isoflavone compounds to its 71 percent owned US subsidiary Marshal Edwards.
Phylogica signs peptide vaccines deal with Pfizer
20 December, 2010 by David BinningPerth drug developer Phylogica has signed a licensing and collaboration agreement with Pfizer which will see the two companies work together to develop novel peptide-based vaccines.
Feature: Manufacturing monoclonal antibodies
20 December, 2010 by Fiona WylieThe journey to market for biological products can be a complex and frustrating process. A key challenge in this process is producing or obtaining the relevant compounds in quantities large enough to support research studies, pre-clinical studies and/or early-stage clinical trials.
China healthcare reforms up the stakes for big pharma: Datamonitor
17 December, 2010 by Staff WritersIt’s a market once deemed ‘too-hard’ by biotech and pharma companies, but with the Chinese government set to spend $US125 billion on healthcare by the end of next year, it’s an opportunity too hot to ignore.
HealthLinx reports solid data from OvPlex study
15 December, 2010 by Staff WritersAustralian diagnostic specialists HealthLinx reported today that the initial data from a second multinational study involving its ovarian cancer diagnostic OvPlex demonstrate a marked increase in diagnostic effectiveness compared to relying only on the standard CA125 blood test.
